中文名 |
枸橼酸托瑞米芬 |
---|---|
英文名 |
Toremifene Citrate |
中文别名 |
2(4-(4-氯-1,2-二苯基-1-丁烯基)苯氧基-N,N-二甲基乙胺枸橼酸盐 | 柠檬酸托瑞米芬 | 2[4-(4-氯-1,2-二苯基-1-丁烯基)苯氧基-N,N-二甲基乙胺枸橼酸盐 |
英文别名 |
更多 |
描述 |
Toremifene(NK 622; FC 1157a)柠檬酸盐是第二代选择性雌激素受体调节剂,对雌激素受体的IC50为1μM。 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
相关类别 |
|
||||||||||||
溶解度 |
体外:
在DMSO中10mM
|
||||||||||||
储备液 |
|
||||||||||||
存储 |
|
||||||||||||
运输 |
室温;可能会有所不同 |
||||||||||||
SMILES |
ClCC/C(C1=CC=CC=C1)=C(C2=CC=C(OCCN(C)C)C=C2)C3=CC=CC=C3.O=C(CC(C(O)=O)(O)CC(O)=O)O |
||||||||||||
参考文献 |
|
||||||||||||
相关活性 小分子 |
Elacestrant dihydrochloride | AZD9496 | 山奈酚 | 3-[4-[[2,4-二(三氟甲基)苄基]氧基]-3-甲氧基苯基]-2-氰基-N-(5-三氟甲基-[1,3,4]噻二唑-2-基)丙烯酰胺 | 雌酚酮 | Brilanestrant | 原人参三醇 | 27-羟基胆固醇 | 己烯雌酚 | PHTPP | 2,3-双(4-羟苯基)丙腈 | 雌马酚 | 胆固醇 | 5,7-二羟黄酮 | Endoxifen Z-异构体盐酸盐 |
密度 | 1.045g/cm3 |
---|---|
沸点 | 535.1?C at 760 mmHg |
熔点 | 158-164?C |
分子式 | C32H36ClNO8 |
分子量 | 598.083 |
闪点 | 277.4?C |
精确质量 | 597.212952 |
PSA | 144.60000 |
LogP | 4.96650 |
外观性状 | 白色或近乎于白色粉末 |
折射率 | 1.416-1.418 |
储存条件 | -20°C Freezer |
水溶解性 | DMSO: >10mg/mL |
枸橼酸托瑞米芬毒性英文版
|
符号 |
GHS05, GHS07, GHS09 |
---|---|
信号词 |
Danger |
危害声明 |
H302-H318-H410 |
警示性声明 |
P280-P301 + P312 + P330-P305 + P351 + P338 + P310 |
危害码 (欧洲) |
Xi: Irritant; |
风险声明 (欧洲) |
R36/37/38 |
安全声明 (欧洲) |
26-37/39 |
危险品运输编码 | UN 3077 9 / PGIII |
RTECS号 | KH2156700 |
海关编码 | 2942000000 |
海关编码 | 2942000000 |
---|
Use of SERMs for treatment in postmenopausal women J. Steroid Biochem. Mol. Biol. 142 , 142-54, (2014)
? FDA approved selective estrogen receptor modulators (SERMs) prevent and treat breast cancer, osteoporosis and dyspareunia. ? SERMs have varying agonist and antagonist activities at the level of the …
|
|
Novel off-target effect of tamoxifen–inhibition of acid ceramidase activity in cancer cells. Biochim. Biophys. Acta 1831(12) , 1657-64, (2013)
Acid ceramidase (AC), EC 3.5.1.23, a lysosomal enzyme, catalyzes the hydrolysis of ceramide to constituent sphingoid base, sphingosine, and fatty acid. Because AC regulates the levels of pro-apoptotic…
|
|
Prostate cancer diagnosis among men with isolated high-grade intraepithelial neoplasia enrolled onto a 3-year prospective phase III clinical trial of oral toremifene. J. Clin. Oncol. 31(5) , 523-9, (2013)
Prostate cancer (PCa) prevention remains an appealing strategy for the reduction of overtreatment and secondary adverse effects. We evaluated the efficacy of toremifene citrate 20 mg in PCa prevention…
|
|
2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine,2-hydroxypropane-1,2,3-tricarboxylic acid |
2-{4-[(1Z)-4-Chloro-1,2-diphenyl-1-buten-1-yl]phenoxy}-N,N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (salt) |
2-{4-[(1Z)-4-Chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate (1:1) |
2-{4-[(1Z)-4-Chloro-1,2-diphenyl-1-buten-1-yl]phenoxy}-N,N-dimethylethanamine 2-hydroxy-1,2,3-propanetricarboxylate (1:1) |
Toremifene Citrate |
2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate (salt) |
ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) |
2-Hydroxypropan-1,2,3-tricarbons?ure–2-{4-[(1Z)-4-chlor-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamin(1:1) |
acide 2-hydroxypropane-1,2,3-tricarboxylique – 2-{4-[(1Z)-4-chloro-1,2-diphénylbut-1-én-1-yl]phénoxy}-N,N-diméthyléthanamine (1:1) |
Ethanamine, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-N,N-dimethyl-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) (salt) |
Toremifene (Citrate) |